Duke Suit Vs. Elan Targets Competing Patent Filings
Duke’s lawsuit, filed last month in U.S. District Court in Durham, North Carolina, accuses Elan of fraud, copyright infringement and unfair competition.
Duke is joined in the suit by Orexigen Therapeutics, a Princeton, a licensee for certain university technology.
Also named as a defendant is Eisai Ltd., the Japanese drug company that bought the rights to the drug and the associated patent application.
Duke has asked the court to declare...
To view the full article, register now.